BlackRock Japan’s Cartesian Therapeutics RNAC Stock Holding History

BlackRock Japan’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21	Closed	-$9K	–	1360
2016 Q3	$9K	Buy	+21	New	+$8.21K	﹤0.01%	1219

Other funds holding RNAC

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock Japan's RNAC Position: Q4 2016 in Review

BlackRock Japan sold out of Cartesian Therapeutics (RNAC) in Q4 2016, closing a stake of 21 shares — an estimated $9K sold.

BlackRock Japan first reported a position in RNAC in Q3 2016 and held it in 1 quarter. The position peaked at $9K in Q3 2016. 43 funds tracked by Wall St. Rank hold RNAC as of Q4 2016.

BlackRock Japan reported no remaining Cartesian Therapeutics position as of Q4 2016 after selling out during the quarter.
BlackRock Japan sold 21 Cartesian Therapeutics shares in Q4 2016, an estimated $9K.
BlackRock Japan first reported a position in Cartesian Therapeutics in Q3 2016 and held it in 1 quarter.
BlackRock Japan's Cartesian Therapeutics position peaked at $9K in Q3 2016.
43 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.